ArticleESMO open2018

BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance.

Chiara Tarantelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.